相关实验视频
Updated: Sep 13, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.8K
在多克索鲁比辛治疗中,FMO2表达赋予心脏保护,同时保持抗瘤活性
Shuyuan Sheng1, Xianpeng Wu1, Changchen Xiao1
1Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; State Key Laboratory of Transvascular Implantation Devices, Heart Regeneration and Repair Key Laboratory of Zhejiang province, Hangzhou 310009, China.
Journal of molecular and cellular cardiology
|August 2, 2025
概括
含有黄素的单氧酶2 (FMO2) 通过增强DNA修复来保护心脏免受多克索鲁比诱导的心肌病 (DIC). 心脏FMO2表达保留了多克索鲁比.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多克索鲁比 (DOX) 化疗导致心脏毒性 (DIC),与氧化应激和DNA损伤有关.
- 含有黄素的单氧化酶2 (FMO2) 是一种心脏酶,在DIC中起着未知的作用.
- 以前的研究表明,FMO2在缺血性心肌病中起着心脏保护作用.
研究的目的:
- 调查FMO2在多克索鲁比诱导心肌病 (DIC) 中的作用.
- 阐明FMO2在心脏中的作用的潜在分子机制.
- 评估FMO2对多克索鲁比辛对瘤的疗效的影响.
主要方法:
- 在野生类型,FMO2绝杀和FMO2过度表达的小鼠中诱导DIC.
- 通过腺病毒操纵评估FMO2在新生小鼠心室肌细胞中的影响.
- 使用转录组分析和染色质分析来识别分子通路.
- 在异种移植模型中评估FMO2对Doxorubicin抗瘤活性的影响.
主要成果:
- 在患有DIC的心脏中,FMO2表达减少.
- 缺乏FMO2会使DIC恶化,而过度表达可以防止心脏损伤.
- FMO2稳定了XLF,促进了DNA修复和减少了DOX诱导的DNA损伤.
- 心脏FMO2表达没有影响多克索鲁比的抗癌疗效.
结论:
- 通过XLF稳定,FMO2表达通过增强DNA修复来保护心脏免受DIC的影响.
- 心脏FMO2是一种潜在的治疗点,用于管理多克索鲁比诱导的心脏毒性.
- FMO2维持了多克索鲁比的抗瘤功效,这表明它具有双重益处.
相关概念视频
01:30Cardiomyopathy II: Dilated Cardiomyopathy
22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
31
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
31
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
48
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
48
01:26Heart Failure Drugs: Inotropic Agents
724
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
724